- Home
- STNG vs AKRO Comparison
STNG vs AKRO Comparison
Compare STNG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- AKRO
- Stock Information
- Founded
- STNG 2009
- AKRO 2017
- Country
- STNG Monaco
- AKRO United States
- Employees
- STNG N/A
- AKRO N/A
- Industry
- STNG Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- STNG Consumer Discretionary
- AKRO Health Care
- Exchange
- STNG Nasdaq
- AKRO Nasdaq
- Market Cap
- STNG 2.7B
- AKRO 2.4B
- IPO Year
- STNG 2010
- AKRO 2019
- Fundamental
- Price
- STNG $52.72
- AKRO $31.20
- Analyst Decision
- STNG Buy
- AKRO Strong Buy
- Analyst Count
- STNG 5
- AKRO 8
- Target Price
- STNG $76.40
- AKRO $46.83
- AVG Volume (30 Days)
- STNG 1.1M
- AKRO 673.4K
- Earning Date
- STNG 10-29-2024
- AKRO 11-08-2024
- Dividend Yield
- STNG 3.04%
- AKRO N/A
- EPS Growth
- STNG 14.72
- AKRO N/A
- EPS
- STNG 13.96
- AKRO N/A
- Revenue
- STNG $1,376,295,000.00
- AKRO N/A
- Revenue This Year
- STNG N/A
- AKRO N/A
- Revenue Next Year
- STNG N/A
- AKRO N/A
- P/E Ratio
- STNG $3.92
- AKRO N/A
- Revenue Growth
- STNG N/A
- AKRO N/A
- 52 Week Low
- STNG $52.07
- AKRO $15.32
- 52 Week High
- STNG $84.67
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- STNG 29.55
- AKRO 51.61
- Support Level
- STNG $53.44
- AKRO $27.05
- Resistance Level
- STNG $56.55
- AKRO $31.60
- Average True Range (ATR)
- STNG 1.70
- AKRO 1.87
- MACD
- STNG 0.28
- AKRO -0.33
- Stochastic Oscillator
- STNG 10.32
- AKRO 47.03
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owns, lease finances or bareboat charters in hundred ten product tankers namely thirty nine LR2 tankers, fifty seven MR tankers and forteeen Handymax tankers. The company's fleet of tankers is the largest, most eco-friendly and newest fleet on the water hauling clean petroleum products. They provide seaborne transportation of crude oil and refined petroleum products worldwide. The company generates majority of its revenue from MR vessel.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.